Septerna (NASDAQ:SEPN) Price Target Raised to $60.00

Septerna (NASDAQ:SEPN) had its price target raised by stock analysts at Stifel Nicolaus from $49.00 to $60.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus‘s target price suggests a potential upside of 18.24% from the company’s current price.

A number of other research firms have also weighed in on SEPN. JonesTrading upped their price objective on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wells Fargo & Company upped their price target on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. HC Wainwright lifted their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $56.44.

Septerna Price Performance

Shares of Septerna stock traded up $0.01 on Tuesday, reaching $50.74. The company had a trading volume of 39,046 shares, compared to its average volume of 363,903. The firm’s 50-day moving average price is $39.76 and its two-hundred day moving average price is $32.71. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -93.08 and a beta of 2.20. Septerna has a 1 year low of $18.19 and a 1 year high of $51.10.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The firm had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. As a group, analysts anticipate that Septerna will post -1.41 EPS for the current year.

Insider Activity

In related news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. The trade was a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel D. Long sold 3,333 shares of Septerna stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 5.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Septerna

Hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC lifted its stake in Septerna by 215.0% in the 3rd quarter. Sterling Capital Management LLC now owns 630 shares of the company’s stock worth $25,000 after purchasing an additional 430 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Septerna during the third quarter worth $93,000. Covestor Ltd grew its holdings in Septerna by 19.0% in the 3rd quarter. Covestor Ltd now owns 2,526 shares of the company’s stock valued at $98,000 after buying an additional 403 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Septerna in the 2nd quarter valued at $211,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Septerna in the 2nd quarter worth $298,000.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.